Xembify Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The xembify market research report is one of a series of new reports that provides xembify market statistics, including the xembify industry global market size, regional shares, competitors with the xembify market share, detailed xembify market segments, market trends, and opportunities, and any further data you may need to thrive in the xembify industry. This xembify market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising global healthcare access, rising healthcare awareness and education, an aging population, better reimbursement policies, and increased focus on rare diseases. Major trends in the forecast period include technological advancements in administration devices, personalized medicine, home healthcare services, improved cold chain logistics, and innovation in immunoglobulin production.

The increasing prevalence of primary immunodeficiency diseases (PI) is expected to contribute to the growth of the xembify market in the coming years. Primary immunodeficiency diseases are conditions where the immune system is either deficient or absent, making the body more vulnerable to infections and illnesses. The rising prevalence of PI is attributed to advancements in diagnostic techniques, greater awareness of these disorders, improvements in genetic testing, and better identification of previously undiagnosed cases. Xembify plays a key role in managing PI by delivering immunoglobulin therapy, which helps enhance the immune system and improve patient outcomes. For example, in August 2023, a report by Thermo Fisher, a U.S.-based life sciences company, estimated that around 6 million people worldwide have a primary immunodeficiency (PID), with approximately 5,000 individuals affected in the UK alone. As a result, the increasing prevalence of PI is expected to drive the growth of the xembify market.

The rise in healthcare spending is also set to drive the growth of the xembify market. Healthcare spending refers to the total financial resources allocated toward healthcare services, including medical research, infrastructure, treatment options, preventive measures, and innovative therapies. The increase in healthcare spending is driven by factors such as the growing prevalence of chronic and rare diseases, advancements in medical technology, greater awareness of health issues, aging populations, and a stronger focus on healthcare infrastructure. Higher spending supports awareness campaigns and screening programs for primary immunodeficiency diseases, leading to earlier diagnosis and earlier intervention with treatments such as Xembify. This, in turn, boosts adoption. For example, according to a report from the Centers for Medicare & Medicaid Services in December 2023, U.S. healthcare spending grew by 4.1% in 2022, totaling $4.5 trillion, a faster rate compared to the 3.2% growth in 2021. This increase in healthcare spending is expected to support the growth of the xembify market.

A key trend in the xembify market is the expansion of indications, such as the introduction of the 20% subcutaneous immunoglobulin (SCIg) product, which provides more flexible dosing options for patients with primary immunodeficiency and other immune-related conditions. The 20% SCIg product is designed to treat primary immunodeficiency and other immune disorders, offering a concentrated form of immunoglobulin G (IgG) administered through subcutaneous injection to boost the immune system. For instance, in July 2024, Grifols, S.A., a pharmaceutical company based in Spain, received approval from the U.S. Food and Drug Administration (FDA) to expand the label for its 20% SCIg product, Xembify, to include treatment-naïve patients with primary humoral immunodeficiencies (PI). This approval marked Xembify as the first 20% SCIg therapy that can be administered without the need for prior intravenous treatment, providing greater flexibility and convenience for patients. This milestone reflects Grifols' commitment to improving patient outcomes through innovative and patient-friendly immunoglobulin therapies.

The key company operating in the xembify market is Grifols S.A.

North America was the largest region in the xembify market in 2024. The regions covered in xembify report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the xembify market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Xembify is a medication under the brand name for immune globulin subcutaneous (human), which is used to treat primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). As a form of immunoglobulin therapy, it helps strengthen the immune system by supplying antibodies (immunoglobulins) that the body may not produce sufficiently.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Xembify is primarily indicated for conditions such as primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, immune thrombocytopenia (ITP), and multifocal motor neuropathy (MMM). Primary immunodeficiency refers to a group of inherited disorders that result in defects in the immune system, making individuals more vulnerable to infections and immune system-related issues. The medication is available through various distribution channels, including direct sales, pharmacies, and online platforms. It is utilized by different end users, including hospitals, clinics, and home care settings.

The xembify market consists of sales of pre-filled syringes, vials, infusion pumps, administration sets, and other required tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.